Literature DB >> 1735230

Serum and other calcium fractions in patients after severe musculoskeletal trauma.

S A Henderson1, H K Graham, R A Mollan.   

Abstract

Alterations in serum calcium fractions after trauma may be of clinical importance. For investigation of this problem, serum calcium fractions were studied prospectively in 42 patients with severe musculoskeletal injuries. The severity of trauma was assessed with the Apache II severity of disease classification system. Serum ionized calcium, total calcium, pH, albumin, and arterial blood gases were measured daily for the first five days after admission. The fat embolism syndrome developed in eight patients; they were more severely injured than the others, and they had significantly lower levels of serum ionized calcium for all five days of the study. There was a strong negative correlation between the Apache II score and serum ionized calcium. Ionized hypocalcemia has a strong association with development of the complications of severe musculoskeletal trauma, such as the fat embolism syndrome.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735230

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Congestive heart failure: where homeostasis begets dyshomeostasis.

Authors:  German Kamalov; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

2.  Changes in plasma ionised calcium within 24 hours of trauma in patients infused with the calcium containing colloid Haemaccel during fluid resuscitation.

Authors:  P A Evans; W Madira; M S Riyatt; M Errington; S Heptinstall
Journal:  J Accid Emerg Med       Date:  1997-03

3.  Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism.

Authors:  German Kamalov; Robert A Ahokas; Wenyuan Zhao; Tieqiang Zhao; Atta U Shahbaz; Patti L Johnson; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.